Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4558558
Max Phase: Preclinical
Molecular Formula: C17H16F6N6O2
Molecular Weight: 450.34
Molecule Type: Unknown
Associated Items:
ID: ALA4558558
Max Phase: Preclinical
Molecular Formula: C17H16F6N6O2
Molecular Weight: 450.34
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C1Nc2[nH]nc(C3CCN(c4cc(C(F)(F)F)ncn4)CC3)c2[C@@H](C(F)(F)F)[C@H]1O
Standard InChI: InChI=1S/C17H16F6N6O2/c18-16(19,20)8-5-9(25-6-24-8)29-3-1-7(2-4-29)12-10-11(17(21,22)23)13(30)15(31)26-14(10)28-27-12/h5-7,11,13,30H,1-4H2,(H2,26,27,28,31)/t11-,13-/m1/s1
Standard InChI Key: XITPNXBXKQPAMW-DGCLKSJQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 450.34 | Molecular Weight (Monoisotopic): 450.1239 | AlogP: 2.56 | #Rotatable Bonds: 2 |
Polar Surface Area: 107.03 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.04 | CX Basic pKa: 3.10 | CX LogP: 2.14 | CX LogD: 2.14 |
Aromatic Rings: 2 | Heavy Atoms: 31 | QED Weighted: 0.61 | Np Likeness Score: -0.97 |
1. (2017) 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative, |
Source(1):